Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR EU) 2018
Authors: Simon O, Wilczynski O, Khalil J
Multiple Sclerosis (MS) is a neurodegenerative disease, characterized by inflammation leading to demyelination and axonal loss. Symptoms of MS such as spasticity, loss of balance or muscle weakness may progressively lead to irreversible disabilities, greatly impacting patients’ overall quality of life. Nearly half (45%) of patients reported experiencing mobility difficulties within a month of diagnosis and nearly all patients (93%) report difficulties within 10 years. The objectives are to assess the impact of walking disability on MS patients’ quality of life and to identify patients’ expectations regarding walking impairment.